Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04902105
Other study ID # EBS-101-HV-102
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 13, 2021
Est. completion date July 6, 2021

Study information

Verified date July 2021
Source Emalex Biosciences Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center, open-label, fixed sequence, drug-drug interaction (DDI) study in healthy subjects.


Description:

Following a 28-day Screening period, eligible subjects will enter the clinical research unit (CRU) and will be enrolled into either Cohort A or B. Subjects in both cohorts will receive a single dose of ecopipam on Day 1. On Day 7, subjects will begin taking a UGT inhibitor according to their assigned cohort. Subjects in Cohort A will receive mefenamic acid 250 mg every 6 hours for 7 days, while subjects in Cohort B will receive divalproex sodium ER 1250 mg once a day for 10 days. A single oral dose of ecopipam will also be administered to Cohort A on Day 7, 1 hour after the first dose of mefenamic acid, and to Cohort B on Day 10, 1 hour after administration of divalproex sodium ER. Subjects in Cohort A will continue taking mefenamic acid through the evening of Day 13 and will remain in the CRU until discharged on Day 14/ET. Subjects in Cohort B will continue taking divalproex sodium ER through Day 16 and will remain in the CRU until discharge on Day 17/ET.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date July 6, 2021
Est. primary completion date July 6, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Male subjects or female subjects of non-childbearing potential - =18 and =55 years of age at the time of consent - BMI >18.5 and <30 kg/m2 and a weight of =50 kg - Sexually active males must use a double barrier method of contraception during the study and for at least 90 days after the last dose of study drug - Male subjects must be willing not to donate sperm until 90 days following the last study drug administration Exclusion Criteria: - Personal or family History of significant medical illness - Clinically significant abnormalities on screening tests/exams - History of or significant risk of committing suicide - Donation of plasma within 7 days prior to dosing - Donation or significant loss of blood within 30 days prior to the first dosing - Major surgery within 3 months or minor surgery within 1 month prior to admission - Use of prohibited prescription, over-the-counter medications or natural health products - Alcohol-based products 24 hours prior to admission - Female subjects who are currently pregnant or lactating - Use of tobacco or nicotine products within 3 months prior to Screening - Significant alcohol consumption - History of drug abuse within the previous 2 years, or a positive drug screen - History of allergy to study medications - Not suitable for study in the opinion of the Principal Investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ecopipam HCL
oral tablets
Mefenamic acid
oral capsules
Divalproex Sodium ER
oral tablets

Locations

Country Name City State
United States Syneos Health Clinical Research Services, LLC. Miami Florida

Sponsors (3)

Lead Sponsor Collaborator
Emalex Biosciences Inc. Nuventra, Syneos Health

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax of ecopipam in the presence of mefenamic acid Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary Cmax of ecopipam in the absence of mefenamic acid Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary Cmax of ecopipam in the presence of divalproex sodium ER Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary Cmax of ecopipam in the absence of divalproex sodium ER Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary AUCinf of ecopipam in the presence of mefenamic acid Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary AUCinf of ecopipam in the absence of mefenamic acid Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary AUCinf of ecopipam in the presence of divalproex sodium ER Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary AUCinf of ecopipam in the absence of divalproex sodium ER Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary AUC0-143 of ecopipam in the presence of mefenamic acid Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary AUC0-143 of ecopipam in the absence of mefenamic acid Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary AUC0-143 of ecopipam in the presence of divalproex sodium ER Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Primary AUC0-143 of ecopipam in the absence of divalproex sodium ER Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary Cmax of EBS-101-40853 Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary AUCinf of EBS-101-40853 Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary AUC0-143 of EBS-101-40853 Up to 35 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary Cmax of mefenamic acid Up to 15 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary Tmax of mefenamic acid Up to 15 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary AUCtau of mefenamic acid Up to 15 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary t½ of mefenamic acid Up to 15 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary Cmax of VPA Up to 19 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary Tmax of VPA Up to 19 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary AUCtau of VPA Up to 19 blood samples will be collected at the indicated time points for pharmacokinetic analysis Up to Day 16
Secondary Safety and tolerability as demonstrated by MOAA/S Safety and tolerability measures will be recorded at the indicated timepoints. Up to Day 17
Secondary Safety and tolerability as demonstrated by C-SSRS Safety and tolerability measures will be recorded at the indicated timepoints. Up to Day 17
Secondary Safety and tolerability as demonstrated by concomitant medications Safety and tolerability measures will be recorded at the indicated timepoints. Up to Day 42
Secondary AEs with relatedness associated with mefenamic acid Subjects will be continually monitored for adverse events Up to Day 42
Secondary AEs with relatedness associated with divalproex sodium ER Subjects will be continually monitored for adverse events Up to Day 42
Secondary AEs with relatedness associated with ecopipam Subjects will be continually monitored for adverse events Up to Day 42
Secondary Absolute values of white blood cell (WBC) count (K/Ul) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Absolute values of neutrophils, lymphocytes, monocytes, eosinophils, and basophils (10E3/uL) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Absolute values of platelets (K/uL) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Absolute values of hematocrit (%) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Absolute values of hemoglobin (g/dL) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Absolute values of Red blood cell (RBC) count (M/uL) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Absolute values of blood sodium, magnesium, urea, phosphorus, potassium, and chloride (mg/dL) Blood samples will be collected for the assessment of clinical chemistry parameters. Up to Day 17
Secondary Absolute values of creatinine, calcium, glucose, and direct and total bilirubin (mg/dL) Blood samples will be collected for the assessment of clinical chemistry parameters. Up to Day 17
Secondary Absolute values of albumin and total protein (g/dL) Blood samples will be collected for the assessment of clinical chemistry parameters. Up to Day 17
Secondary Absolute values of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), and creatinine phosphokinase (CPK) Blood samples will be collected for the assessment of clinical chemistry parameters. Up to Day 17
Secondary Absolute values of urine specific gravity Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Absolute values of urine pH Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Absolute values of urine glucose Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Absolute values of urine protein Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Absolute values of urine blood Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Absolute values of urine ketones Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Absolute values of urine bilirubin, urobilinogen, and nitrite Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Absolute values of urine leukocytes by dipstick Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in white blood cell (WBC) count (K/Ul) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in neutrophils, lymphocytes, monocytes, eosinophils, and basophils (10E3/uL) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in platelets (K/uL) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in hematocrit (%) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in hemoglobin (g/dL) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in Red blood cell (RBC) count (M/uL) Blood samples will be collected for the assessment of hematology parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in blood sodium, magnesium, urea, phosphorus, potassium, and chloride (mg/dL) Blood samples will be collected for the assessment of clinical chemistry parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in creatinine, calcium, glucose, and direct and total bilirubin (mg/dL) Blood samples will be collected for the assessment of clinical chemistry parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in albumin and total protein (g/dL) Blood samples will be collected for the assessment of clinical chemistry parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), and creatinine phosphokinase (CPK) (U/L) Blood samples will be collected for the assessment of clinical chemistry parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in urine specific gravity Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in urine pH Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in urine glucose Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in urine protein Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in urine blood Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in urine ketones Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in urine bilirubin, urobilinogen, and nitrite (Milligrams per deciliter) Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Change from Day -1 to Day of Discharge in urine leukocytes by dipstick Urine samples will be collected for the assessment of urine parameters. Up to Day 17
Secondary Change from Day 6 to Day of Discharge in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (U/L) Blood samples will be collected for the assessment of clinical chemistry parameters. Up to Day 17
Secondary Absolute values of electrocardiogram (ECG) parameters: PR, QRS, QT, and QT interval corrected for heart rate using Fridericia's formula (QTcF) (Milliseconds) Twelve-lead ECGs will be obtained with the participant in a supine position after a rest of at least 5 minutes using an automated ECG machine. PR, QRS, QT, and QTcF intervals will be measured. Up to Day 10
Secondary Change from pre-dose for the respective day in ECG parameters: PR, QRS, QT, and QTcF (Milliseconds) Twelve-lead ECGs will be obtained with the participant in a supine position after a rest of at least 5 minutes using an automated ECG machine. PR, QRS, QT, and QTcF intervals will be measured. Up to Day 10
Secondary Absolute values of oral temperature (degrees Celsius) Temperature will be assessed as part of vital signs. Up to Day 17
Secondary Change from pre-dose for the respective day in oral temperature (degrees Celsius) Temperature will be assessed as part of vital signs. Up to Day 17
Secondary Absolute values of heart rate (beats/minute) Heart rate will be assessed as part of vital signs. Up to Day 17
Secondary Change from pre-dose for the respective day in heart rate (beats/minute) Heart rate will be assessed as part of vital signs. Up to Day 17
Secondary Absolute values of respiratory rate (breaths/minute) Respiratory rate will be assessed as part of vital signs. Up to Day 17
Secondary Change from pre-dose for the respective day in respiratory rate (breaths/minute) Respiratory rate will be assessed as part of vital signs. Up to Day 17
Secondary Absolute values of systolic blood pressure (SBP) and diastolic blood pressure (DBP) (mmHG) Blood pressure will be assessed as part of vital signs. Up to Day 17
Secondary Change from pre-dose for the respective day in SBP and DBP (mmHG) Blood pressure will be assessed as part of vital signs. Up to Day 17
See also
  Status Clinical Trial Phase
Completed NCT04645940 - Fruquintinib Food Effect and Proton Pump Inhibitor Study Phase 1
Completed NCT04540965 - Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects Phase 1
Completed NCT04531072 - Effect of Atazanavir-ritonavir on the Pharmacokinetics and Toxicity of Lumefantrine Phase 4
Completed NCT03385525 - Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074 Phase 1
Completed NCT05680792 - Pharmacokinetic Interaction Between Nitazoxanide and Atazanavir/Ritonavir in Healthy Volunteers N/A
Completed NCT05137548 - A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects Phase 1
Not yet recruiting NCT05525351 - The Application and Validation of Triple Drug Response Surface Models on Density Spectral Array in Clinical Anesthesia
Terminated NCT01980342 - Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz Phase 4
Completed NCT04080596 - DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin Phase 1
Recruiting NCT04593680 - Assessment of Drug-drug Interactions Between Masculinizing Hormone Therapy and Antiretroviral Agents Concomitantly for Pre-exposure Prophylaxis Among Transgender Men N/A
Active, not recruiting NCT04590417 - Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women N/A
Completed NCT05633147 - Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam Phase 1
Completed NCT02391688 - Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail Phase 1
Completed NCT00806299 - Loperamide Grapefruit Juice Interaction PK Trial Phase 1
Completed NCT03336346 - Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana
Completed NCT04818086 - Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder Phase 1/Phase 2
Completed NCT03187015 - A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects Phase 1
Not yet recruiting NCT04463576 - Drug Interactions in Hospital Information System. The PRoSIT System..
Not yet recruiting NCT03920566 - The Effect of ENZAlutamide on the Anti-Xa Levels of Patients Receiving DOACs
Completed NCT03011996 - To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration Phase 1